These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38036098)

  • 1. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
    Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
    Peptides; 2024 May; 175():171111. PubMed ID: 38036098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
    Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
    Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.
    Zirafi O; Hermann PC; Münch J
    J Leukoc Biol; 2016 Jun; 99(6):863-8. PubMed ID: 26965637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
    Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
    Hatse S; Bridger G; de Clercq E; Schols D
    Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
    Kaiser LM; Harms M; Sauter D; Rawat VPS; Glitscher M; Hildt E; Tews D; Hunter Z; Münch J; Buske C
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
    Harms M; Habib MMW; Nemska S; Nicolò A; Gilg A; Preising N; Sokkar P; Carmignani S; Raasholm M; Weidinger G; Kizilsavas G; Wagner M; Ständker L; Abadi AH; Jumaa H; Kirchhoff F; Frossard N; Sanchez-Garcia E; Münch J
    Acta Pharm Sin B; 2021 Sep; 11(9):2694-2708. PubMed ID: 34589390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and characterization of an endogenous CXCR4 antagonist.
    Zirafi O; Kim KA; Ständker L; Mohr KB; Sauter D; Heigele A; Kluge SF; Wiercinska E; Chudziak D; Richter R; Moepps B; Gierschik P; Vas V; Geiger H; Lamla M; Weil T; Burster T; Zgraja A; Daubeuf F; Frossard N; Hachet-Haas M; Heunisch F; Reichetzeder C; Galzi JL; Pérez-Castells J; Canales-Mayordomo A; Jiménez-Barbero J; Giménez-Gallego G; Schneider M; Shorter J; Telenti A; Hocher B; Forssmann WG; Bonig H; Kirchhoff F; Münch J
    Cell Rep; 2015 May; 11(5):737-47. PubMed ID: 25921529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
    Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
    J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
    Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
    BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer.
    Xu Q; Wang Z; Chen X; Duan W; Lei J; Zong L; Li X; Sheng L; Ma J; Han L; Li W; Zhang L; Guo K; Ma Z; Wu Z; Wu E; Ma Q
    Oncotarget; 2015 Mar; 6(7):4717-32. PubMed ID: 25605248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
    Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
    Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4.
    Marchesi F; Monti P; Leone BE; Zerbi A; Vecchi A; Piemonti L; Mantovani A; Allavena P
    Cancer Res; 2004 Nov; 64(22):8420-7. PubMed ID: 15548713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells.
    Shen B; Zheng MQ; Lu JW; Jiang Q; Wang TH; Huang XE
    Asian Pac J Cancer Prev; 2013; 14(9):5403-8. PubMed ID: 24175834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.
    Harms M; Fabech Hansson R; Gilg A; Almeida-Hernández Y; Löffler J; Rodríguez-Alfonso A; Habib MMW; Albers D; Ahmed NS; Abadi AH; Winter G; Rasche V; Beer AJ; Weidinger G; Preising N; Ständker L; Wiese S; Sanchez-Garcia E; Zelikin AN; Münch J
    J Med Chem; 2023 Nov; 66(22):15189-15204. PubMed ID: 37940118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
    Jung CK; Münch J; Jacob T
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The
    Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability.
    Harms M; Haase A; Rodríguez-Alfonso A; Löffler J; Almeida-Hernández Y; Ruiz-Blanco YB; Albers D; Gilg A; von Bank F; Zech F; Groß R; Datta M; Jaikishan J; Draphoen B; Habib M; Ständker L; Wiese S; Lindén M; Winter G; Rasche V; Beer AJ; Jumaa H; Abadi AH; Kirchhoff F; Busch M; Dünker N; Sanchez-Garcia E; Münch J
    J Control Release; 2024 Jul; 373():583-598. PubMed ID: 39047872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.